Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic study in young patients with chronic kidney disease stage G5 from unknown etiology. The GENSEN study design Estudio genético en pacientes jóvenes con enfermedad renal crónica avanzada de etiología no filiada. Diseño del estudio GENSEN

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Quiroga, Borja|||0000-0001-5730-1929
  • García-Aznar, José M.
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • de Sequera, Patricia|||0000-0001-7705-9228
Introduction: Chronic kidney disease (CKD) of unknown etiology is one of the main causes of renal replacement therapy in our environment. Previous studies in other territories suggest that hereditary diseases could be one of the potential causes of this pathology, especially in younger patients. The GENSEN study will evaluate the presence of pathogenic genetic variants in subjects who have developed CKD category G5 before the age of 46, of unknown etiology. Methods: Observational, prospective and multicenter study, which evaluates the diagnostic usefulness of massive high-throughput sequencing (HTS) directed at a set of genes, in identifying the cause of CKD. Patients from all over Spain will be included, from whom a blood or saliva sample will be extracted, subsequently analyzing a panel of 529 genes associated with hereditary kidney disease. This publication communicates the study protocol and design. Conclusion: The GENSEN study will allow to evaluate the diagnostic performance of a gene panel study in young subjects from our environment with the development of category G5 CKD without a clear cause. An etiological diagnosis would offer potential benefits for patients and relatives (targeted therapies, clinical trials, detection of extrarenal manifestations, evaluation of relatives for living kidney donation, estimation of the risk of recurrence in the kidney graft, genetic counseling, among others) and would allow genetic study to be brought closer to nephrology in our country.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe, findings from the ERA Registry

  • Abd ElHafeez, Samar|||0000-0002-3250-2780
  • Kramer, A.|||0000-0002-7560-2669
  • Arici, Mustafa
  • Arnol, Miha
  • Åsberg, Anders|||0000-0002-0628-1769
  • Bell, Samira
  • Belliere, Julie
  • Díaz-Corte, Carmen
  • Fernández Fresnedo, Gema
  • Hemmelder, Marc
  • Heylen, Line|||0000-0002-4595-0195
  • Hommel, Kristine
  • Kerschbaum, J.|||0000-0002-6896-2279
  • Naumović, Radomir
  • Nitsch, Dorothea
  • Santamaría, Rafael
  • Finne, Patrik
  • Palsson, Runolfur
  • Pippias, Maria
  • Resić, Halima
  • Rosenberg, Mai
  • Santiuste de Pablos, Carmen
  • Segelmark, M.|||0000-0002-1221-0772
  • Sørensen, Søren Schwartz
  • Soler, María José|||0000-0003-3621-0766
  • Vidal, Enrico
  • Jager, Kitty|||0000-0003-0444-8569
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Stel, Vianda S.
Primary glomerular disease (PGD) is a major cause of end-stage kidney disease (ESKD) leading to kidney replacement therapy (KRT). We aimed to describe incidence (trends) in individuals starting KRT for ESKD due to PGD and to examine their survival and causes of death. We used data from the European Renal Association (ERA) Registry on 69 854 patients who started KRT for ESKD due to PGD between 2000 and 2019. ERA primary renal disease codes were used to define six PGD subgroups. We examined age and sex standardized incidence, trend of the incidence and survival. The standardized incidence of KRT for ESKD due to PGD was 16.6 per million population (pmp), ranging from 8.6 pmp in Serbia to 20.0 pmp in France. Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) had the highest incidences, of 4.6 pmp and 2.6 pmp, respectively. Histologically non-examined PGDs represented over 50% of cases in Serbia, Bosnia and Herzegovina, and Romania and were also common in Greece, Estonia, Belgium and Sweden. The incidence declined from 18.6 pmp in 2000 to 14.5 pmp in 2013, after which it stabilized. All PGD subgroups had 5-year survival probabilities above 50%, with crescentic glomerulonephritis having the highest risk of death [adjusted hazard ratio 1.8 (95% confidence interval 1.6-1.9)] compared with IgAN. Cardiovascular disease was the most common cause of death (33.9%). The incidence of KRT for ESKD due to PGD showed large differences between countries and was highest and increasing for IgAN and FSGS. Lack of kidney biopsy facilities in some countries may have affected accurate assignment of the cause of ESKD. The recognition of the incidence and outcomes of KRT among different PGD subgroups may contribute to a more individualized patient care approach. OrderedDict([(u'fig', OrderedDict([(u'@position', u'float'), (u'@id', u'ga1'), (u'label', u'Graphical Abstract'), (u'graphic', OrderedDict([(u'@xlink:href', u'gfae034fig1g'), (u'@position', u'float')]))]))]).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ageing meets kidney disease

  • Ortiz, Alberto|||0000-0002-9805-9523
  • Mattace-Raso, Francesco
  • Soler, María José|||0000-0003-3621-0766
  • Fouque, Denis
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for ˃3 months, with implications for health. The most used diagnostic criteria are a urinary albumin: creatinine ratio ≥30 mg/g or an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2. Either of these diagnostic thresholds is associated with adverse health outcomes. GFR decreases with age and the prevalence of CKD is highest in older adults; moreover, the presence of CKD is associated with an increased risk of all-cause and cardiovascular death related to accelerated ageing in all age ranges, and the absolute increase in risk is highest for those aged ˃75 years. Indeed, premature death is a more common outcome than CKD progression to kidney failure requiring kidney replacement therapy. The progressive ageing of the world population contributes to the projection that CKD will become the second most common cause of death before the end of the century in countries with long life expectancy. The current collection of selected studies on kidney disease and ageing published in Age&Ageing, NDT and CKJ provides an overview of key topics, including cognitive decline, sarcopaenia, wasting and cardiovascular and non-cardiovascular morbidity and mortality, the management of kidney failure and gender differences in CKD progression.